Pethidine

Alcohol co-use, Benzodiazepine co-use, Other opioid co-use, GHB/GBL co-use, Barbiturate co-use

All CNS depressant combinations with pethidine produce additive respiratory depression that is frequently fatal. This is a class-level opioid contraindication but is particularly relevant given pethidine's additional anticholinergic cardiovascular effects.

Patients with existing seizure disorders face elevated risk from normeperidine's pro-convulsant properties. Even single therapeutic doses lower the seizure threshold, and the risk escalates with cumulative dosing.

Combining pethidine with SSRIs produces additive serotonin reuptake inhibition, elevating serotonin syndrome risk. Confirmed in animal models (SERT-deficient mice) and clinical case reports.

In hepatic impairment, oral bioavailability increases from ~50% to 80-90% and parent drug half-life extends to 7-11 hours. This produces disproportionately higher plasma concentrations for a given dose, elevating both opioid toxicity and normeperidine production risk.

Severe renal impairment prevents adequate clearance of the neurotoxic metabolite normeperidine, which accumulates and produces agitation, myoclonus, and tonic-clonic seizures. These effects are not reversible by naloxone.

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin, grapefruit juice) substantially elevate pethidine plasma levels by reducing hepatic clearance. This can precipitate overdose even at standard therapeutic doses.

Pethidine crosses the placenta and can cause neonatal respiratory depression. While historically used in labour analgesia, Cochrane evidence suggests inferior efficacy and more adverse effects compared to alternatives.

The 2023 AGS Beers Criteria classifies pethidine as a medication to always avoid in older adults (strong recommendation, moderate evidence). Risks include delirium, normeperidine neurotoxicity from age-related renal decline, and inefficacy as an oral analgesic at commonly used doses.

Concurrent or recent (within 14 days) use of any monoamine oxidase inhibitor is absolutely contraindicated. The interaction produces either an excitatory reaction (serotonin syndrome: hyperthermia, rigidity, clonus, death) or a depressant reaction (coma, respiratory failure, cardiovascular collapse). This is the most dangerous drug interaction in opioid pharmacology.

Clinical guidelines specify a maximum 48-hour duration of pethidine use due to normeperidine accumulation. Even in patients with normal renal function, repeated dosing beyond this window produces neurotoxic metabolite levels sufficient to cause seizures.

Sickle cell disease patients historically treated with pethidine for vaso-occlusive crises experienced normeperidine toxicity (seizures, agitation) due to high cumulative dosing requirements. Current emergency medicine guidelines discourage or prohibit pethidine use in this population.

Chronic use of pethidine for cancer pain management produces progressive normeperidine accumulation. Historical case series documented neurotoxicity in cancer patients on high cumulative doses. Contemporary guidelines universally recommend against pethidine for chronic cancer pain.